2.
小鼠异种移植肿瘤模型中待测药物的体内相对肿瘤体积增殖率
The relative tumor volume proliferation rate of test articles in the xenograft models
| Drugs | Dose/(mg/kg) | T/C in the xenograft models/% | |||||
| BT-474 | HCC1954 | SK-OV-3 | NCI-N87 | MDA-MB-468 | |||
| *P<0.05, compared with control group. n=9 in the xenograft model NCI-N87, others n=10,x±sx. HER2, human epidermal growth factor receptor 2; ADC, antibody drug conjugate. | |||||||
| Control | 0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | |
| 0.55 | 38.1±0.8* | 25.8±1.0* | 79.2±1.4 | 65.5±1.2 | 101.3±1.4 | ||
| Anti-HER2-ADC | 1.67 | 5.0±0.2* | 1.0±0.0* | 26.0±1.1* | 56.6±1.3 | 106.1±2.2 | |
| 5.00 | 1.0±0.1* | 0.2±0.0* | 10.9±1.3* | 2.8±0.3* | 110.5±1.4 | ||
| 0.55 | 50.8±1.8 | 96.0±3.3 | 90.2±1.8 | 122.4±2.0 | |||
| Ado-trastuzumab emtansine | 1.67 | 7.9±0.5* | 66.1±1.3 | 71.8±2.1 | 111.2±2.4 | ||
| 5.00 | 7.1±0.6* | 24.0±0.8* | 54.9±1.7 | 127.0±1.9 | |||
| Trastuzumab | 5.00 | 62.1±1.9 | 42.9±1.6 | 72.7±1.2 | 79.1±1.9 | 149.1±1.8 | |
| Paclitaxel | 15.00 | 53.3±0.8 | 26.1±0.6* | 71.7±2.5 | 59.5±1.4 | 32.9±1.0* | |